These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30560106)

  • 1. Application of Small Epigenetic Modulators in Pediatric Medulloblastoma.
    Zwergel C; Romanelli A; Stazi G; Besharat ZM; Catanzaro G; Tafani M; Valente S; Mai A
    Front Pediatr; 2018; 6():370. PubMed ID: 30560106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia.
    Lu R; Wang GG
    Front Oncol; 2017; 7():241. PubMed ID: 29075615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.
    Yuan J; Llamas Luceño N; Sander B; Golas MM
    Cell Oncol (Dordr); 2017 Jun; 40(3):263-279. PubMed ID: 28429280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
    Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR
    Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors.
    Wadhwa E; Nicolaides T
    Cureus; 2016 May; 8(5):e620. PubMed ID: 27382528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic regulation in medulloblastoma.
    Yi J; Wu J
    Mol Cell Neurosci; 2018 Mar; 87():65-76. PubMed ID: 29269116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibition of LSD1 activity blocks REST-dependent medulloblastoma cell migration.
    Callegari K; Maegawa S; Bravo-Alegria J; Gopalakrishnan V
    Cell Commun Signal; 2018 Sep; 16(1):60. PubMed ID: 30227871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of epigenetic modulators as a powerful adjuvant for breast cancer therapies.
    Claude-Taupin A; Boyer-Guittaut M; Delage-Mourroux R; Hervouet E
    Methods Mol Biol; 2015; 1238():487-509. PubMed ID: 25421676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic events in medulloblastoma development.
    Lindsey JC; Anderton JA; Lusher ME; Clifford SC
    Neurosurg Focus; 2005 Nov; 19(5):E10. PubMed ID: 16398460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
    Chistiakov DA; Orekhov AN; Bobryshev YV
    Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the PI3K/AKT/mTOR signaling pathway in medulloblastoma.
    Dimitrova V; Arcaro A
    Curr Mol Med; 2015; 15(1):82-93. PubMed ID: 25601471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in epigenetic glioblastoma therapy.
    Lee DH; Ryu HW; Won HR; Kwon SH
    Oncotarget; 2017 Mar; 8(11):18577-18589. PubMed ID: 28099914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights.
    Khatua S; Song A; Citla Sridhar D; Mack SC
    Curr Neuropharmacol; 2018; 16(7):1045-1058. PubMed ID: 29189165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma.
    Ribeiro ML; Reyes-Garau D; Armengol M; Fernández-Serrano M; Roué G
    Front Genet; 2019; 10():986. PubMed ID: 31681423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medulloblastoma molecular dissection: the way toward targeted therapy.
    Remke M; Ramaswamy V; Taylor MD
    Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medulloblastoma development: tumor biology informs treatment decisions.
    Gopalakrishnan V; Tao RH; Dobson T; Brugmann W; Khatua S
    CNS Oncol; 2015; 4(2):79-89. PubMed ID: 25768332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
    Morel D; Almouzni G; Soria JC; Postel-Vinay S
    Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and Recent Advances in Medulloblastoma Therapy.
    Kumar V; Kumar V; McGuire T; Coulter DW; Sharp JG; Mahato RI
    Trends Pharmacol Sci; 2017 Dec; 38(12):1061-1084. PubMed ID: 29061299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular insights into pediatric brain tumors have the potential to transform therapy.
    Gajjar A; Pfister SM; Taylor MD; Gilbertson RJ
    Clin Cancer Res; 2014 Nov; 20(22):5630-40. PubMed ID: 25398846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
    Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
    Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.